Susmita Roy
Good afternoon, everyone. My name is Susmita Roy. I’m an associate on the health care investment banking team here at JPMorgan. On behalf of JPMorgan, first of all, welcome. Thank you so much for taking the time to attend the conference. It’s been a great conference so far. And to continue the festivities rolling, I’m thrilled to introduce Entrada Therapeutics for their company presentation today.
A little bit about Entrada before we get started. Entrada is focused on treating devastating diseases with intracellular targets. Last week, Entrada highlighted an important progress across its EEV portfolio for neuromuscular and ocular diseases. The company is advancing multiple clinical programs in people living with Duchenne muscular dystrophy in the U.K., EU and the U.S. In 2026, Entrada expects to have 4 clinical stage programs in its DMD franchise, complementing the ongoing clinical programs, progress of its myotonic dystrophy type 1 partnership, VX-670 with Vertex. The year is shaping up to have several value-driving catalysts.
I’m pleased to welcome on stage next to me, Entrada’s Chief Executive Officer, Dipal Doshi, who can share more about Entrada’s year ahead. And also on stage, we’ll have Natarajan as well. Thank you for joining us this afternoon. I’m really pleased to hand it off to the team.
Dipal Doshi
CEO & Director
Great. Thank you. Thanks for the kind introduction and to the JPMorgan team for inviting us here to present. I look forward to talking more about the work that we’re doing at Entrada.
Before I go too far, it’s the normal disclaimer about making forward-looking statements. So just refer to our SEC filings
